All News
Sleep disturbance common and associated with disease activity (both PRO and physician-assessed) in RA. Need further studies to evaluate causal directions, but may well be bidirectional? Abstr#1666 #ACR21 @RheumNow https://t.co/eK65I92wPg
Richard Conway RichardPAConway ( View Tweet)
#ACR21 Ab#1683: ABA for RA-ILD
⭐️Stabilization of DLCO, FVC, HRCT in UIP and NSIP in 106 UIP, 84 NSIP patients
⭐️Stabilization or improvement of dyspnea in 91% UIP, 95% NSIP pts
@Rheumnow https://t.co/qfgDmooGOj https://t.co/gz6Jk15nUs
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Ab#1699: ITIS diet:
⭐️Fatigue ⬇️ in 20 pts on ITIS trial, didn't correlate with final DAS28CRP
⭐️Fatigue responders (50% improvement) had different fecal microbiome changes & anti-inflamm compounds, than non-responders
@Rheumnow https://t.co/UvE2ZpxCDU
Links:
Eric Dein ericdeinmd ( View Tweet)
☄️Late breakingTRAIL1 RCT Pirfenidone on RA-ILD.
✨Primary outcome on incidence of decline of >10% FVC or death not met 11% PIR vs. 15% PBO OR=0.67 p=0.48
BUT
✨underpowered
✨reduces decline in FVC(ml) over 52wk (-66 vs. -146, p=0.0082)
✨safety ok
#ACR21 #AbstL10
@RheumNow https://t.co/IxYDE3lN1s
Aurelie Najm AurelieRheumo ( View Tweet)
Safety update for #filgotinib in #RA over ~2.2yrs treatment
👉🏼Well-tolerated with no ne safety concerns since 2020
👉🏼AE incidence rates decreased or remained stable
👉🏼Slight incr rates of NMSC & non-NMSC malignancies
Abs#1698 #ACR21 @RheumNow
https://t.co/0jbZFVgiyN https://t.co/yOlntLwQlU
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#1655. Respiratory Ifn in RA on bDMARD
▶️1 group was initiated into vaccination program vs usual care
⭐️Vaccinated group had ⬇️ admissions from respiratory ifns. 44% ⬇️ severe resp ifn
💉programs work!
@Rheumnow https://t.co/pljR6DbAtU https://t.co/goSHGID8qG
Links:
Eric Dein ericdeinmd ( View Tweet)
#Multimorbidity in women with #rheumatoidarthritis is increased compared to men with RA. However, women and men without RA have similar levels of multimorbidity.
Abs#1656 #ACR21 @RheumNow
https://t.co/iXhXOldTy0 https://t.co/CsOM7odE69
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#1658 - Autoimmune Risks in Relatives of RA pts. 1st degree relatives have risk of:
▶️ AI thyroid (OR 1.3)
▶️ Celiac (1.5)
▶️ SLE (1.3)
▶️ IBD - no ⬆️ risk
⭐️1st, 2nd, 3rd degree relativ: ⬆️ risk of RA
⭐️2nd degree: ⬆️ risk SLE
https://t.co/ATHdemoF45 @Rheumnow #ACRbest https://t.co/JcuZmg9L8E
Links:
Eric Dein ericdeinmd ( View Tweet)
GLORIA RCT: 400+ pts. Low dose Pred in RA >65yo on top of other treatments 2yrs.
Authors conclude benefit/risk balance in favour of GCs 🧐
2 thoughts:
1️⃣ CV risk linked to GCs ⬆️ over time and cumulative dose: Follow up= short!
2️⃣ Small # for CV events
#ACR21 #Abst 1678 @RheumNow https://t.co/QECJR68ZJu
Aurelie Najm AurelieRheumo ( View Tweet)
What is the likelihood of developing an #autoimmunedisease in first-degree relatives of pts with #RA?
Genealogical & phenotypic data suggests lower threshold for screening for autoimmune thyroiditis, #coeliac & #SLE in FDRs.
Abs#1658 #ACR21 @RheumNow
https://t.co/PdSZ05elsf https://t.co/AkIXDkWCM8
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts:
❌No ⬆️ in disease activity scores post-vaccination
❌No serious adverse event
▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls
⭐️RTX and MMF ⬇️ responses
@Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW
Links:
Eric Dein ericdeinmd ( View Tweet)
Dr Coras on "ITIS" anti-inflammatory diet in RA. Improves fatigue after 2 weeks. Fatigue response dissociated from disease activity response. Open label, but promising. Fatigue remains one of our biggest challenges in RA. Abstr#1699 #ACR21 @RheumNow @ElenaNikiUK https://t.co/tBMqmWAy8m
Richard Conway RichardPAConway ( View Tweet)
#Depression is associated with a 3x increased mortality risk in patients with incident #RA.
👉🏼Results from #DANBIO
👉🏼~11000 RA pts, ~1000 starting antidepressants
Abs#1659 #ACR21 @RheumNow
https://t.co/SsEjmLzacP https://t.co/1GiFE0KLjK
Mrinalini Dey DrMiniDey ( View Tweet)
#ACR21 L10 TRAIL1: Pirfenidone for RA-ILD
⭐️Low pt enrollment due to pandemic, 1/2 of planned trial size
▶️ Unable to meet primary endpt (composite death+FVC) but met FVC markers. Most pronounced in UIP patterns on HRCT
@Rheumnow https://t.co/HB7N9Wl9Dn https://t.co/muBEguAAja
Links:
Eric Dein ericdeinmd ( View Tweet)
#Sleep disturbance is common in #RA but does it correlate with disease activity?
Results from >100 RA pts suggest yes.
Many reported sleep disturbances, associated with both incr patient & physician-assessed disease activity.
Abs#1666 #ACR21 @RheumNow
https://t.co/ud2uMf25cI https://t.co/BE4UHPB0f1
Mrinalini Dey DrMiniDey ( View Tweet)
Predicting RA, and Treatment of Subclinical Arthritis
Dr. Meral K. El Ramahi ( @MeralElRamahiMD) shares the abstracts discussed at #ACR21 focusing on predicting RA and treating subclinical arthritis.
https://t.co/DYgV43JpgT https://t.co/U2NfXrfYZU
Links:
Dr. John Cush RheumNow ( View Tweet)
My article on the potential use of BMI to guide biologic selection in RA. Discussing #ACR21 abstract 0588 by @MilenaGianfran @JYazdanyMD https://t.co/hxliSZ3IBS @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Watch my video discussion of #ACR21 abstract 564 from @KronzerMD @jeffsparks on the association of upper airways disease with incident RA. https://t.co/Nkg9Yl9yYT @RheumNow
Richard Conway RichardPAConway ( View Tweet)
Avoid IFX drug holidays!
In this study 400+ pts
Dvlpmt of ADAs associated w/
▶️RA vs. SPA OR 2.1
▶️Smoking OR 1.8
▶️Drug holidays > 11 weeks OR 4.1
▶️High DA OR 1.5
while
◀️Concomitant IS drug OR 0.4
◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh
Aurelie Najm AurelieRheumo ( View Tweet)
Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis
👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA
👉🏼No new safety risks with long-term use
👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX
Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
Mrinalini Dey DrMiniDey ( View Tweet)
